| Literature DB >> 26879379 |
Tshepo Malesela Mafokwane1, Amidou Samie2.
Abstract
BACKGROUND: Chlamydia is a bacterial infection that has long plagued humanity as the most commonly contracted STD and is caused by Chlamydia trachomatis. With the emergence of HIV/AIDS, sexually transmitted diseases have also re-emerged as a grave public health problem, particularly in developing countries. Updated Information about the relative frequencies in developing countries is sparse. This study aims at establishing the relative occurrence of chlamydia using real time PCR technique in the Vhembe District of South Africa where reports on the prevalence of chlamydia are not available.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26879379 PMCID: PMC4754813 DOI: 10.1186/s13104-016-1887-8
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Fig 1Amplification and melt curves obtained from the Light Cycler 480 II after real time PCR amplification of Chlamydia trachomatis DNA from the urine samples obtained from HIV positive and HIV negative patients visiting HIV care centres. a shows the amplification curves and b shows the melting curve analysis. The minor picks appearing at around 74 °C on the melting curves are probably due to the primer dimers
Distribution of chlamydia in the study population by origin, age, gender and marital status
| Variables | Characteristics | Total (N) | Chlamydia positive N (%) | Statistics (Chi square and P value) | OR (odd ratio), 95 % CI (confidence interval) |
|---|---|---|---|---|---|
| Origin | Elim | 50 | 16 (32.0) | χ2 = 0.00, P = 0.987 | OR = 0.994, 95 % CI 0.0511–1.937 |
| Tshilidzini | 66 | 18 (27.3) | χ2 = 0.968, P = 0.325 | OR = 0.731, 95 % CI 0.38–1.35 | |
| Donald Fraser | 119 | 41 (34.50) | χ2 = 0.593, P = 0.441 | OR = 1.23, 95 % CI 0.721–2.12 | |
| Univen | 8 | 3 (37.5) | χ2 = 0.111, P = 0.739 | OR = 1.28, 95 % CI 0.29–5.49 | |
| Gender | Female | 171 | 67 (39.2) | χ2 = 12.888, P = 0.001 | OR = 3.514, 95 %CI 1.723–7.16 |
| Male | 71 | 11 (15.5) | |||
| Marital status | Single | 102 | 28 (27.5) | χ2 = 3.99, P = 0.174 | OR = 0.681, 95 % CI 0.391–1.187 |
| Married | 90 | 29 (32.2) | χ2 = 0.00, P = 0.998 | OR = 0.999, 95 % CI 0.572–1.746 | |
| Divorced | 20 | 7 (35.0) | χ2 = 0.077, P = 0.782 | OR = 1.145, 95 %CI 0.438–2.994 | |
| Widowed | 30 | 14 (46.7) | χ2 = 3.267, P = 0.071 | OR = 2.023, 95 % CI 0.932–4.392 | |
| Age groups | 19–24 | 5 | 5 (20) | χ2 = 2.112, P = 0.146 | OR = 0.476, 95 % CI 0.171–1.320 |
| 25–45 | 135 | 48 (35.6) | χ2 = 1.015, P = 0.314 | OR = 1.332, 95 % CI 0.762–2.327 | |
| Above 45 | 74 | 24 (32.4) | χ2 = 0.111, P = 0.916 | OR = 0.969, 95 % CI 0.538–1.744 | |
| HIV Status | HIV negative | 8 | 3 (37.5) | χ2 = 0.111, P = 0.739 | OR = 0.918, 95 % CI 0.533–1.581 |
| HIV positive | 75 (31.9) | ||||
| ARV | Taking ARVs | 154 | 43 (28.5) | χ2 = 2.989, P = 0.130 | OR = 0.647, 95 % CI 0.368–0.138 |
| Not taking ARVs | 84 | 32 (38.1) |
Occurrence of Chlamydia in a HIV population in relation to antiretroviral treatment
| Treatment | Count | Chlamydia positive (%) | Statistics (χ2, P value) | OR (odd ratio and 95 % confidence interval) |
|---|---|---|---|---|
| Not on ARV | 84 | 32 (38.1) | χ2 = 2.365, P = 0.124 | OR 0.649, 95 % CI 0.374–1.228 |
| On ARV | 133 | 37 (27.8) | ||
| Zidovudine | 12 | 6 (50) | χ2 = 3.158, P = 0.076 | OR 2.871, 95 % CI 0.861–9.562 |
| Efavirenz | 114 | 29 (25.4) | χ2 = 2.784, P = 0.095 | OR 0.426, 95 % CI 0.154–1.184 |
| Lamivudine | 129 | 36 (27.9) | χ2 = 0.043, P = 0.836 | OR: 0.774, 95 % CI 0.068–8.804 |
| Tenofovir | 42 | 11 (26.2) | χ2 = 0.103, P = 0.748 | OR 0.873, 95 % CI 0.383–1.993 |
| Nevirapine | 15 | 7 (46.7) | χ2 = 2.914, P = 0.088 | OR 0.426, 95 % CI 0.154–1.184 |
| Stavudine | 81 | 23 (28.4) | χ2 = 0.014, P = 0.906 | OR 1.048, 95 % CI 0.479–2.291 |
Occurrence of chlamydia in the study population in relation to gender and pregnancy
| Population | Count | Chlamydia positive (%) | Statistics (χ2, P value) | OR (odd ratio and 95 % confidence interval) |
|---|---|---|---|---|
| Males | 65 | 10 (15.4) | χ2 = 12.88, P = 0.0001 | OR 3.514, 95 % CI 1.723–7.165 |
| Non-pregnant females | 136 | 48 (35.3) | χ2 = 3.376, P = 0.066 | OR 2.095, 95 % CI 0.943–4.658 |
| Pregnant females | 30 | 16 (53.3) | χ2 = 7.289, P = 0.007 | OR 2.837, 95 % CI 1.302–6.186 |
| Total | 231 | 74 (32) | χ2 = 7.183, P = 0.007 | OR 2.818, 95 % CI 1.292–6.144 |
Impact of socio-economic status of patients on the prevalence of chlamydia
| Variables | Characteristics | Total (N) | Positive N (%) | Statistics |
|---|---|---|---|---|
| Income range less than 1000 | Yes | 96 | 34 (35.4) | χ2 = 0.425, P = 0.515, OR = 1.204, 95 % CI 0.68–2.103 |
| No | 131 | 41 (31.3) | ||
| Number of dependents | 1–3 dependents | 87 | 26 (29.9) | χ2 = 0.474, P = 0.491, OR = 0.816, 95 % CI 0.457–1.456 |
| 4–6 dependents | 98 | 33 (33.7) | χ2 = 0.093, P = 0.760, OR 1.093, 95 % CI 0.622–1.915 | |
| 7–13 | 38 | 13 (34.2) | χ2 = 0.093, P = 0.760, OR = 1.092, 95 % CI 0.522–2.283 | |
| Education | Primary school | 64 | 17 (26.6) | χ2 = 1.533, P = 0.216, OR = 0.670, 95 % CI 0.355–1.266 |
| Secondary school | 128 | 46 (35.9) | χ2 = 1.259, P = 0.262, OR = 1.367, 95 % CI 0.0.791–2.364 | |
| Tertiary school | 20 | 6 (30.0) | χ2 = 0.076, P = 0.782, OR = 0.869, 95 % CI 0.321–2.356 | |
| No education | 26 | 9 (34.6) | χ2 = 0.045, P = 0.832, OR = 1.097, 95 % CI 0.465–2.586 |
Prevalence of chlamydia in relation to the symptoms experienced by the patients
| Characteristic | Total | Positive N (%) | Statistics: χ2, P value | OR, 95 % CI (odd ratio, 95 % confidence interval) |
|---|---|---|---|---|
| Pain (general body pain) | ||||
| No | 127 | 40 (31.5) | χ2 = 0.646, P = 0.412 | OR 1.265, 95 % CI 0.712–2.24 |
| Yes | 87 | 32 (36.5) | ||
| Fever | ||||
| No | 151 | 54 (35.8) | χ2 = 1.029, P = 0.310 | OR 0.719, 95 % CI 0.37–1.36 |
| Yes | 63 | 18 (28.6) | ||
| Current chest pain | ||||
| No | 194 | 58 (29.9) | χ2 = 2.440, P = 0.118 | OR 1.675, 95 % CI 0.87–3.21 |
| Yes | 48 | 20 (41.7) | ||
| Allergy (any type of allergy) | ||||
| No | 180 | 49 (27.2) | χ2 = 6.841, P = 0.009 | OR 2.202, 95 % CI 1.21–4.05 |
| Yes | 62 | 28 (45.2) | ||
| Sores in genitals | ||||
| No | 220 | 73 (33.2) | χ2 = 1.251, P = 0.263 | OR 0.559, 95 % CI 0.20–1.56 |
| Yes | 23 | 5 (21.7) | ||
| Sores on lips | ||||
| No | 208 | 67 (32.2) | χ2 = 0.008, P = 0.927 | OR 0.965, 95 % CI 0.44–2.08 |
| Yes | 35 | 11 (31.4) | ||
| Genital warts | ||||
| No | 212 | 71 (33.5) | χ2 = 1.477, p = 0.224 | OR 0.579, 95 % CI 0.23–1.41 |
| Yes | 31 | 7 (22.6) | ||
| Rash in genitals | ||||
| No | 150 | 45 (30) | χ2 = 0.001, P = 0.969 | OR 0.982, 95 % CI 0.40–2.41 |
| Yes | 27 | 8 (29.6) | ||
| Mouth thrush last 3 months | ||||
| No | 213 | 67 (31.5) | χ2 = 0.490, P = 0.484 | OR 1.332, 95 % CI 0.59–2.97 |
| Yes | 29 | 11 (37.9) | ||
| Vision problem | ||||
| No | 156 | 49 (31.4) | χ2 = 0.034, P = 0.854 | OR 1.054, 95 % CI 0.60–1.85 |
| Yes | 86 | 28 (32.6) | ||
| Blurry vision | ||||
| No | 41 | 16 (39) | χ2 = 1.962, P = 0.165 | OR 0.521, 95 % CI 0.20–1.31 |
| Yes | 44 | 11 (25.0) | ||
| Blind spot | ||||
| No | 72 | 23 (31.9) | χ2 = 0.007, P = 0.933 | OR 0.947, 95 % CI 0.26–3.39 |
| Yes | 13 | 4 (30.8) | ||
| STD (general STI symptoms) | ||||
| No | 191 | 64 (33.5) | χ2 = 1.027, P = 0.311 | OR 697, 95 % CI 0.34–1.40 |
| Yes | 50 | 13 (26.0) | ||
| Diabetes | ||||
| No | 237 | 78 (32.9) | χ2 = 2.908, P = 0.088 | OR 0.671, 95 % CI 0.61–0.733 |
| Yes | 6 | 0 (0.0) | ||
| Hypertension | ||||
| No | 233 | 74 (31.8) | χ2 = 0.299, P = 0.585 | OR 1.432, 95 % CI 0.39–5.22 |
| Yes | 10 | 4 (40.0) | ||
| Epilepsy | ||||
| No | 241 | 77 (32) | χ2 = 0.296, P = 0.586 | OR 2.13, 95 % CI 0.130–34.50 |
| Yes | 2 | 1 (50) | ||
| Skin problem | ||||
| No | 154 | 50 (32.5) | χ2 = 0.082, P = 0.774 | OR 0.921, 95 % CI 0.52–1.62 |
| Yes | 88 | 27 (30.7) | ||
| Past skin problem | ||||
| No | 167 | 54 (32.3) | χ2 = 0.161, P = 0.688 | OR 0.887, 95 % CI 0.48–1.60 |
| Yes | 74 | 22 (29.7) | ||
Prevalence of chlamydia in relation to the sexual behavior of the participants
| Variables | Characteristics | Total (N) | Positive N (%) | Statistics | |
|---|---|---|---|---|---|
| Age at first sex | 12–15 years | 16 | 7 (43.8) | χ2 = 0.691, P = 0.406, | OR = 1.544, 95 % CI 0.551–4.327 |
| 16–18 years | 108 | 42 (38.9) | χ2 = 2.056, P = 0.152, | OR = 1.511, 95 % CI 0.858–2.662 | |
| 19–22 years | 70 | 20 (28.6) | χ2 = 3.633, P = 0.045, | OR = 0.681, 95 % CI 0.367–1.264 | |
| 23 years and above | 16 | 5 (22) | χ2 = 3.633, P = 0.057, | OR = 0.254, 95 % CI 0.056–1.149 | |
| No of sex partners since first sex | 1–4 sex partners | 129 | 48 (37.2) | χ2 = 0.889, P = 0.346, | OR = 1.33, 95 % CI 0.73–2.427 |
| 5–9 sex partners | 38 | 12 (31.6) | χ2 = 0711, P = 0.646, | OR = 0.838, 95 % CI 0.395–1.781 | |
| More than 10 partner | 40 | 12 (30.0) | χ2 = 0.500, P = 0.480, | OR = 0.764, 95 % CI 0.362–1.612 | |
| No of sex partners the previous year | 0 partners | 64 | 20 (31.3) | χ2 = 0.412, P = 0.521, | OR = 0.815, 95 % CI 0.436–1.524 |
| 1 partner | 114 | 44 (38.6) | χ2 = 1.893, P = 0.169, | OR = 1.496, 95 % CI 0.842–2.657 | |
| 2–4 partners | 27 | 7 (25.9) | χ2 = 0.992, P = 0.319, | OR = 0.631, 95 % CI 0.254–1.571 | |
| 5 or more partners | 7 | 2 (28.6) | χ2 = 0.110, P = 0.740, | OR = 0.755, 95 % CI 0.143–3.990 | |
| Condom use | Always | 84 | 24 (29.8) | χ2 = 1.841, P = 0.175 | OR = 0.605, 95 % CI 0.292–1.253 |
| Never | 13 | 4 (30.8) | χ2 = 0.070, P = 0.791, | OR = 0.847, 95 % CI 0.246–2.913 | |
| Sometimes | 38 | 17 (44.7) | χ2 = 2.677, P = 0.102, | OR = 1.898, 95 % CI 0.876–4.113 | |
| Currently abstaining from sex | No | 46 | 46 (34.2) | χ2 = 0.000, P = 0.988, | OR = 1.005, 95 % CI 0.559–1.804 |
| Yes | 27 | 27 (34.1) | |||